Videos

Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br /> &nbsp;

Ethan Basch, MD, MSc, recently received the Clinical Research Award from the Association of Community Cancer Centers during the 2019 National Oncology Conference. Basch explains the importance of receiving this award in light of his work around patient-reported outcomes for symptom monitoring in oncology.

Ali McBride, PharmD, MS, BCOP, discussed during the recent National Oncology Conference his goals for ACCC while serving as president, which include focusing on education, innovation, and compensation.<br /> &nbsp;

Ovarian Cancer

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br /> &nbsp;

Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti&ndash;PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br /> &nbsp;

Kerry Rogers, MD,&nbsp;discusses the rationale for evaluating ibrutinib in patients with hairy cell leukemia in the phase II trial.

Fred R. Hirsch, MD, PhD, discusses how genomic testing has expanded over the last few years and has impacted the lung cancer treatment paradigm.

Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha&ndash;positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.

Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.

Pinkal Desai, MD, discusses the factors a practicing physician should consider when selecting an appropriate induction therapy for patients with acute myeloid leukemia.

William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non&ndash;small cell lung cancer.

Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.